Tae-Won Kim, PhDExecutive Director Toxicology at Ionis Pharmaceuticals
Tae-Won Kim received his Ph.D in the Department of Environmental and Molecular Toxicology from North Carolina State University at Raleigh in 1996, studying skin carcinogenesis model. Following his Ph.D., he was a post-doctoral fellow at University of California, San Francisco until 1997. His postgraduate training included research in the areas of tumor metastasis and oral carcinogenesis. He then joined SUGEN as a toxicologist in the Department of PK and Toxicology. Along with a team of dedicated colleagues, he was a Group Leader Toxicologist for SUTEN project until 2001. Then, he joined Ionis Pharmaceuticals Inc. until now. He is currently, Executive Director of Toxicology and has participated in the development of Kynamro, Inotersen, Volanesorsen and multiple 2¢-MOE modified phosphorothioate antisense oligonucleotides with/without covalently bound to triantenary N-acetyl galactosamine (GalNAc3) conjugate.